High potency of BC133 in T-cell–mediated eradication of established human AML xenografts in vivo. (A-B) Female NSG mice were implanted IV with 1 million MOLM13 AML cells. Tumor growth was monitored by bioluminescence imaging (A) and expressed as total flux in photons/second (p/s) (B). Starting 7 days after leukemia implantation, activated T cells (ATCs; 5 million-10 million per dose) were injected once per week for 3 weeks. The dose of BC133 was titrated down (from 100 μg to 0.1 μg) and administered 1 day before and 1 day after each T-cell administration. To support T-cell survival in vivo, 1000 IU IL-2 was injected subcutaneously 2 to 3 times per week. Data from 2 independent experiments were pooled. (C-D) When tumor signal in mice treated with T cells only reached 10¹⁰ p/s, 100 μg per dose BC133 treatment was started (twice per week) without further T-cell injection. Tumor growth was monitored by bioluminescence imaging (C) and expressed as total flux in p/s (D).